Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 28.06 |
| Open | 27.31 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 28.06 - 28.06 |
| 52-week range | 26.25 - 34.47 |
| Volume | |
| Avg. volume | 33,128 |
| Market cap | 44.118B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 33.41 |
| EPS (TTM) | 0.84 |
| Earnings date | N/A |
| Forward dividend & yield | 1.39 (4.95%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
ZacksShould Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Business Wire
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
OSAKA, Japan & CAMBRIDGE, Mass., December 05, 2023--Takeda (TSE:4502/NYSE:TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000.
Business WireTakeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
OSAKA, Japan & CAMBRIDGE, Mass., November 27, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego. Takeda’s latest research focuses on improving treatment options for those living with hematologic diseases.
